Capecitabine Global Market Report 2024

The capecitabine market size has grown strongly in recent years. It will grow from $2.06 billion in 2023 to $2.25 billion in 2024 at a compound annual growth rate (CAGR) of 9.4%. The growth observed in the historic period can be attributed to advancements in chemotherapy, the convenience offered by oral administration, regulatory approvals, improved accessibility to treatments, and recommendations from oncologists. These factors collectively contributed to the increased adoption and utilization of capecitabine in the management of metastatic breast and colorectal cancers. The evolution of chemotherapy practices, coupled with the convenience of oral delivery, played a significant role in shaping the historical growth trajectory of capecitabine.

The capecitabine market size is expected to see strong growth in the next few years. It will grow to $3.14 billion in 2028 at a compound annual growth rate (CAGR) of 8.7%. The anticipated growth in the forecast period can be attributed to factors such as expanded indications for capecitabine, ongoing research in combination therapies, development of healthcare infrastructure, government initiatives supporting cancer care, and increased adoption in developing countries. Notable trends expected in the forecast period include the exploration of targeted therapy combinations, expanded use in adjuvant settings, the integration of biomarker-driven treatment approaches, advancements in pharmacogenomics, and the implementation of telehealth monitoring in cancer care. These trends indicate a dynamic landscape with a focus on personalized and comprehensive approaches to cancer treatment.

The projected rise in cancer cases is anticipated to be a major driver behind the expansion of the capecitabine market. Cancer, a diverse spectrum of diseases characterized by abnormal cell growth that often spreads uncontrollably, poses a significant health challenge across various organs and tissues. Capecitabine, a chemotherapeutic agent, plays a crucial role in cancer treatment by enzymatically transforming into the antimetabolite fluorouracil within tumors. This conversion inhibits DNA synthesis, effectively slowing down the growth of tumor tissue. Notably, in 2021, the American Cancer Society reported approximately 1.9 million new cancer cases and 608,570 cancer-related deaths in the United States, marking an increase from the 1.8 million new cases and 606,520 deaths reported in 2020. This escalating incidence of cancer serves as a primary factor driving the expansion of the capecitabine market.

The upsurge in clinical trials stands poised to significantly impact the growth trajectory of the capecitabine market. Clinical trials, pivotal research studies evaluating the safety and efficacy of medical interventions or drugs in human subjects, play a crucial role in assessing capecitabine's potential across diverse cancer types. These trials constitute a fundamental phase in the drug development process, providing essential data for regulatory approval and eventual public use. As of May 2023, reports from Xtalks, a Canadian advertising services company, indicate a global registration of 452,604 clinical trials on ClinicalTrials.gov, signifying a substantial increase from the previously reported over 365,000 trials in early 2021. This surge in clinical trials underscores their pivotal role in advancing capecitabine's potential applications, consequently fueling the growth of the capecitabine market.

The trend of product innovations has gained significant traction. Notably, major companies operating within the capecitabine market have directed their efforts towards developing generic tablets as a strategic approach to augment their revenues. A prime example occurred in February 2021 when Dr. Reddy's Laboratories, an India-based pharmaceutical company, introduced Capecitabine tablets - an FDA-approved generic variant of Xeloda - into the United States market. Specifically utilized in cancer treatment, these tablets are available in 150 mg and 500 mg strengths, offered in bottle counts of 60 and 120, respectively.

Prominent companies are focusing on the development of innovative drug formulations, such as dispersible tablets, aimed at enhancing patient compliance and securing a competitive advantage. Dispersible tablets represent a pharmaceutical dosage form designed for rapid dissolution in liquid for convenient administration. An illustrative instance took place in December 2022, when Shilpa Medicare Ltd., an India-based pharmaceutical company, launched Capecitabine 1000 MG under the brand Capebel. Distinguished as the world's inaugural dispersible tablet tailored for colorectal and metastatic breast cancer, this innovative product utilizes advanced technology for swift dispersion within a remarkable 90-second timeframe. As such its existing counterparts in 500 mg and 150 mg strengths, this novel tablet allows patients to dissolve it in 100 ml of water, offering a more manageable solution, particularly beneficial for cancer patients contending with swallowing difficulties. Such pioneering formulations exemplify a strategic approach adopted by companies within the capecitabine market to cater to patient needs while introducing groundbreaking pharmaceutical solutions.

In January 2023, Cheplapharm Arzneimittel GmbH, a pharmaceutical company based in Germany, completed the acquisition of the commercial rights for Xeloda (capecitabine) in China from F. Hoffmann-La Roche AG, a healthcare company based in Switzerland. The transaction, conducted for an undisclosed amount, is part of Cheplapharm's strategic efforts to fortify its oncology portfolio and expand its footprint in the pharmaceutical market. F. Hoffmann-La Roche AG is the producer of Xeloda, an oral chemotherapy drug containing capecitabine.

Major companies operating in the capecitabine market report are Pfizer Inc., Merck & Co. Inc., Bayer AG, Novartis AG, Sanofi S.A., Sensus Healthcare Inc., Fresenius SE & Co. KGaA, GlaxoSmithKline PLC, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Inc., Genentech Inc., Aurobindo Pharma Limited, Dr Reddy Laboratories Ltd., Sigma-Aldrich Corp, Cipla Inc., Hikma Pharmaceuticals PLC, Lupin Limited, Alkem Laboratories Limited, Ranbaxy Laboratories Ltd., Glenmark Pharmaceuticals Ltd., Accord Healthcare Ltd., Zentiva N.V., Reliance Life Sciences Pvt Ltd., Avita Medical Limited, Mylan Inc., Sandoz Inc.

North America was the largest region in the capecitabine market in 2023. The regions covered in the capecitabine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the capecitabine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Capecitabine drugs come in two main types such as branded and generic. Branded drugs are medical substances available only with a prescription from a qualified physician or authorized prescriber, following state or federal regulations. These drugs are used either alone or in combination to address metastatic colon cancer. Various formulations, such as tablets and capsules, make up the drug forms, and they are distributed through channels including hospital pharmacies, online pharmacies, and retail pharmacies. Capecitabine is applied in diverse medical contexts, including the treatment of colon cancer, rectal cancer, breast cancer, gastric cancer, and more. End-users encompass hospitals, homecare services, specialty centers, and other healthcare providers.

The capecitabine market research report is one of a series of new reports that provides capecitabine market statistics, including capecitabine industry global market size, regional shares, competitors with a capecitabine market share, detailed capecitabine market segments, market trends and opportunities, and any further data you may need to thrive in the capecitabine industry. This capecitabine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The capecitabine market consists of sales of croscarmellose sodium, anhydrous lactose, hydroxypropyl methylcellulose, magnesium stearate, and microcrystalline cellulose. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.